PubMed:24088574 JSONTXT

{"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":133,"end":144},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":145,"end":216},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":217,"end":351},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":352,"end":502},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":503,"end":597},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":598,"end":606},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":607,"end":747},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":748,"end":873},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":874,"end":1093},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1094,"end":1106},"obj":"Sentence"},{"id":"TextSentencer_T12","span":{"begin":1107,"end":1349},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":132},"obj":"Sentence"},{"id":"T2","span":{"begin":133,"end":144},"obj":"Sentence"},{"id":"T3","span":{"begin":145,"end":216},"obj":"Sentence"},{"id":"T4","span":{"begin":217,"end":351},"obj":"Sentence"},{"id":"T5","span":{"begin":352,"end":502},"obj":"Sentence"},{"id":"T6","span":{"begin":503,"end":597},"obj":"Sentence"},{"id":"T7","span":{"begin":598,"end":606},"obj":"Sentence"},{"id":"T8","span":{"begin":607,"end":747},"obj":"Sentence"},{"id":"T9","span":{"begin":748,"end":873},"obj":"Sentence"},{"id":"T10","span":{"begin":874,"end":1093},"obj":"Sentence"},{"id":"T11","span":{"begin":1094,"end":1106},"obj":"Sentence"},{"id":"T12","span":{"begin":1107,"end":1349},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":4,"end":8},"obj":"gene:596"},{"id":"T1","span":{"begin":103,"end":131},"obj":"disease:C0023449"},{"id":"T2","span":{"begin":4,"end":8},"obj":"gene:596"},{"id":"T3","span":{"begin":103,"end":131},"obj":"disease:C1961102"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"},{"id":"R2","pred":"associated_with","subj":"T2","obj":"T3"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":145,"end":173},"obj":"HP_0006721"},{"id":"T2","span":{"begin":165,"end":173},"obj":"HP_0001909"},{"id":"T3","span":{"begin":209,"end":215},"obj":"HP_0002664"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}

{"project":"Allie","denotations":[{"id":"SS1_24088574_2_0","span":{"begin":145,"end":173},"obj":"expanded"},{"id":"SS2_24088574_2_0","span":{"begin":175,"end":178},"obj":"abbr"}],"relations":[{"id":"AE1_24088574_2_0","pred":"abbreviatedTo","subj":"SS1_24088574_2_0","obj":"SS2_24088574_2_0"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"24088574-0#4#8#gene596","span":{"begin":4,"end":8},"obj":"gene596"},{"id":"24088574-0#103#131#diseaseC0023449","span":{"begin":103,"end":131},"obj":"diseaseC0023449"},{"id":"24088574-0#103#131#diseaseC1961102","span":{"begin":103,"end":131},"obj":"diseaseC1961102"}],"relations":[{"id":"4#8#gene596103#131#diseaseC0023449","pred":"associated_with","subj":"24088574-0#4#8#gene596","obj":"24088574-0#103#131#diseaseC0023449"},{"id":"4#8#gene596103#131#diseaseC1961102","pred":"associated_with","subj":"24088574-0#4#8#gene596","obj":"24088574-0#103#131#diseaseC1961102"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}

{"project":"DisGeNet-2017-sample","denotations":[{"id":"T782","span":{"begin":4,"end":8},"obj":"gene:596"},{"id":"T783","span":{"begin":103,"end":131},"obj":"disease:C0023449"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T782","obj":"T783"},{"id":"R2","pred":"associated_with","subj":"T782","obj":"T783"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"The BCL2-938 C \u003e A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.\nBACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. While current treatment regimens achieve almost 80% overall survival, long-term side effects of chemotherapeutic agents can be severe. The functional BCL2-938C \u003e A promoter polymorphism is known to influence the balance between survival and apoptosis of malignant hematolymphoid cells. We investigated its usefulness as a marker for treatment stratification for children with ALL.\nMETHODS: We analyzed DNA from 182 children suffering from ALL in this study to determine genotypes of the -938 C \u003e A polymorphism by \"slow-down\" PCR.\nRESULTS: ALL patients with the BCL2-938CC genotype had an approximately 3-fold higher risk of belonging to a high-risk group. Within the high-risk group, 50% of BCL2-938CC patients were classified as high-risk due to poor prednisone response whereas only 33% of patients with AC and AA genotypes were classified as high-risk for the same reason.\nCONCLUSIONS: Our results suggest that BCL2-938C \u003e A genotyping may be beneficial for therapy response prediction in ALL patients, and warrant examination in a larger cohort to validate its usefulness for treatment stratification of pediatric ALL patients."}